News and features
Read the latest news and features about our world-leading research, discoveries, fundraising and philanthropy. If you want to keep updated on our news, you can follow us on social media or sign up for our Search newsletter.
If you’re a journalist and want to find out more, you can contact our media relations team.
ESMO 2018: Cancer trial shows treating the prostate directly with radiotherapy improves survival
Treating the prostate with radiotherapy alongside standard treatment led to a 11 per cent increase in survival for some men with advanced prostate cancer, according to a new study.
Fewer but larger radiation doses cause similarly low side-effects as conventional breast cancer radiotherapy
Women who received radiotherapy for early-stage breast cancer in fewer, larger doses experienced similarly low rates of late-onset side-effects as those receiving conventional treatment, results from a 10-year study show.
ESMO 2018: Major trial shows targeted drug – palbociclib – extends breast cancer survival
Combining a targeted drug with hormone therapy substantially extends survival for women with advanced breast cancer, a major clinical trial has found.
The ICR responds to the FDA approval of talazoparib for women with BRCA-mutant advanced breast cancer
The ICR strongly welcomes the news that talazoparib (trade name Talzenna) has been approved by the US Food and Drug Administration (FDA) for patients with advanced breast cancer.
New study discovers inhibitors of protein linked to the devastating childhood brain cancer DIPG
Scientists at The Institute of Cancer Research, London in collaboration with a team at the Structural Genomics Consortium in Oxford (SGC) have created a new series of compound that could form the basis for drugs that target the devastating childhood brain cancer diffuse intrinsic pontine glioma, or DIPG.
Having a heavier first-born child or a shorter pregnancy may increase a mother’s risk of breast cancer
Short first pregnancies and having a heavier first-born child may slightly increase a mother’s risk of breast cancer, a new study has found.
#teamICR take on the Royal Parks Half Marathon 2018
22 members of #teamICR will be running the Royal Parks Half Marathon this Sunday to raise money for cancer research.
What the future holds for children with brain cancer
Brain cancer is a devastating disease, particularly when it affects young children, and progress in treatments has been slow. But ICR researchers have made major breakthroughs in recent months, with discoveries that could impact diagnosis, treatment and survival from childhood brain tumours.
Experts call for genetic testing to personalise treatment for all children assessed for new cancer treatments
All children with cancer should have the genetic profile of their tumour comprehensively analysed when being considered for new treatments, say leading childhood cancer experts.
-being-attacked-by-two-cytotoxic-t-cells-(red)-547x410.tmb-hbmobile.png?Culture=en&sfvrsn=8f59440b_2 "Immunotherapy - Oral squamous cancer cell (white) being attacked by two cytotoxic T cells (red) 547x410")
Scientists make important breakthrough in understanding our immune system
Researchers have discovered how a key element of our body’s response to diseases works, answering a long-standing and important question in the field of studies of the immune system.
First patient in the UK receives pioneering new form of radiotherapy
The ICR and the Royal Marsden have delivered the first ever treatment in the UK using a Magnetic Resonance Linear Accelerator (MR Linac) machine.
Cancer researchers, family and friends gather to celebrate award of Queen’s Regius Professorship to Professor Johann de Bono
Colleagues from across cancer research, family and friends came together to celebrate and mark the achievements of the ICR's Professor Johann de Bono, as he delivered a celebratory lecture to mark his appointment as the ICR's first Regius Professor of Cancer Research.
